Scabies in babies

Hill, Taryn Anne; Cohen, Bernard

doi:10.1111/pde.13255

Cited by 35 publications

(56 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Few treatments of scabies with permethrin 5 % cream have been described in infants younger than two months – three such children in one report and a four‐week‐old in another. Permethrin 5 % cream was well tolerated in these cases . We extend and confirm its efficacy and good tolerance in a larger case series.…”

Section: Discussionsupporting

confidence: 71%

Topical scabies therapy with permethrin is effective and well tolerated in infants younger than two months

Hoffmann

Mößner

Schön

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Background and objectives Proper management of infantile scabies is indispensable in order to prevent prolonged duration and spread of the disease. Data are still lacking that support topical treatment with permethrin 5 % cream in infants under two months of age, and application remains off‐label for this age group. Patients and methods We identified infants younger than two months who suffered from scabies in order to evaluate the safety and efficacy of topical treatment with permethrin cream in this age group. Diagnosis of scabies was based on the typical symptoms and pathognomonic features as determined with dermoscopy. We analyzed the efficacy and safety of the therapies that were applied. Results Seven scabies patients under two months of age were treated with permethrin 5 % cream. Topical therapy was repeated up to three times in four patients due to incomplete resolution or recurrence of skin lesions. Conclusions Permethrin therapy was well tolerated in all seven infants, even when conducted several times. Our results confirm that the use of permethrin 5 % cream in children younger than two months of age is safe.

show abstract

Section: Discussionsupporting

confidence: 71%

Topical scabies therapy with permethrin is effective and well tolerated in infants younger than two months

Hoffmann

Mößner

Schön

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…2 While scabies affects both adults and children, and although the epidemiological data concerning the incidence of scabies in infants are poor, both a high prevalence and a specific clinical phenotype have been shown in infants. [3][4][5] Several topical treatments, including permethrin, benzyl benzoate and sulfur ointment, have been approved for the treatment of scabies in infants and are regularly prescribed. However, their thorough and consistent application to the skin is not always easy for families.…”

Section: What Does This Study Add?mentioning

confidence: 99%

“…In France, the annual incidence has been estimated at 330 cases per 100 000 inhabitants and it seems to have increased over the past 10 years . While scabies affects both adults and children, and although the epidemiological data concerning the incidence of scabies in infants are poor, both a high prevalence and a specific clinical phenotype have been shown in infants . Several topical treatments, including permethrin, benzyl benzoate and sulfur ointment, have been approved for the treatment of scabies in infants and are regularly prescribed.…”

mentioning

confidence: 99%

Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study

et al. 2019

View full text Add to dashboard Cite

Summary Background Scabies is a frequent condition seen in infants and children. Only topical treatments have been approved in infants, but some of them are poorly tolerated. Oral ivermectin is approved for the treatment of scabies in several countries, but its use in infants and children weighing < 15 kg is off label. Objectives To assess the safety of ivermectin in infants and young children, and to collect data on ivermectin efficacy in these age groups. Methods This study was performed in the dermatology and paediatric dermatology departments of 28 French centres between July 2012 and November 2015. Physicians treating an infant or child weighing < 15 kg for scabies with oral ivermectin were asked to send back a completed standardized and anonymous questionnaire, and the data were analysed. Results Data were collected on 170 infants and children aged 1–64 months, with a body weight of 4–14·5 kg, who were treated with oral ivermectin. The mean dose received was 223 μg kg–1 and 89% of the patients received a systematic second dose. Concomitant topical treatment was administered to 73% of patients. Adverse events were reported in seven patients (4%) and were not severe. At the follow‐up visit, 139 (85%) patients had achieved healing. Factors significantly associated with healing were an ivermectin dose > 200 μg kg–1 (P < 0·001), and a delay between those two doses of < 10 days (P = 0·025). Conclusions Our findings suggest the safety and efficacy of ivermectin for the treatment of scabies in infants and young children. What's already known about this topic? Scabies is a frequent condition in small children and infants, but the therapeutic options are limited. Ivermectin has been approved for the treatment of scabies in adults and children > 15 kg, but its use is off‐label in infants and children weighing < 15 kg. Safety data on the use of ivermectin in children weighing < 15 kg are limited. What does this study add? Of 170 infants and children weighing < 15 kg who were treated for scabies with oral ivermectin, there were only seven reported mild adverse events and no serious ones. Our results show that ivermectin is effective in treating scabies in 85% of patients. Efficacy is higher when the received dose exceeds 200 μg kg–1 and when the delay between the two doses is < 10 days. Respond to this article

show abstract

“…Bislang wurden nur wenige Therapien der Skabies mit Permethrin‐Creme 5 % bei Kindern unter zwei Monaten beschrieben: drei Säuglinge unter zwei Monaten in einem Bericht und ein vier Wochen altes Baby in einem weiteren Bericht. In all diesen Fällen wurde die Permethrin‐Creme 5 % gut vertragen . Wir erweitern die Datenlage und bestätigen die Wirksamkeit und eine gute Verträglichkeit in einer größeren Fallserie.…”

Section: Schlussfolgerungenunclassified

Gute Verträglichkeit und Wirkung der topischen Skabiestherapie mit Permethrin bei Kindern unter zwei Monaten

Hoffmann

Mößner

Schön

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Hintergrund und Ziele Bei Skabies im Kindesalter ist ein adäquates Management unverzichtbar, um einer verlängerten Krankheitsdauer vorzubeugen und die weitere Ausbreitung der Erkrankung zu verhindern. Noch fehlen die Daten, die die topische Anwendung von Permethrin 5 % bei Säuglingen unter zwei Monaten unterstützen; die Anwendung in dieser Altersgruppe ist daher ein Off‐Label‐Use. Patienten und Methodik Um Sicherheit und Wirksamkeit der topischen Therapie mit Permethrin‐Creme in dieser Altersgruppe zu untersuchen, ermittelten wir an Skabies erkrankte Säuglinge, die jünger als zwei Monate waren. Die Diagnosestellung der Skabies erfolgte aufgrund der charakteristischen Symptomatik und der pathognomischen Befunde in der Dermatoskopie. Wir untersuchten die Wirksamkeit und Sicherheit der angewendeten Therapien. Ergebnisse Sieben Skabies‐Patienten unter zwei Monaten wurden mit Permethrin‐Creme 5 % behandelt. Bei vier Patienten wurde die topische Therapie aufgrund einer unvollständigen Remission oder dem Wiederauftreten der Hautveränderungen bis zu dreimal wiederholt. Schlussfolgerungen Die Permethrin‐Therapie wurde von allen sieben Säuglingen gut vertragen, auch bei mehrmaliger Anwendung. Unsere Ergebnisse bestätigen, dass die Anwendung von Permethrin‐Creme 5 % bei Säuglingen unter zwei Monaten sicher ist.

show abstract

Scabies in babies

Cited by 35 publications

References 13 publications

Topical scabies therapy with permethrin is effective and well tolerated in infants younger than two months

Topical scabies therapy with permethrin is effective and well tolerated in infants younger than two months

Ivermectin safety in infants and children under 15 kg treated for scabies: a multicentric observational study

Gute Verträglichkeit und Wirkung der topischen Skabiestherapie mit Permethrin bei Kindern unter zwei Monaten

Contact Info

Product

Resources

About